CD47 inhibitors(Cluster of differentiation 47 inhibitors), MYC inhibitors(Myc proto-oncogene protein inhibitors), NLRP3 inhibitors(NACHT, LRR and PYD domains-containing protein 3 inhibitors)

Therapeutic Areas

NeoplasmsRespiratory DiseasesMouth and Tooth Diseases+ [4]

Active Indication

Small Cell Lung CancerStomatitisEndometriosis+ [3]

Inactive Indication

Advanced biliary tract cancerAdvanced cancerAdvanced Malignant Solid Neoplasm+ [14]

Originator Organization

EPICENTRE Biotechnologies LLC

Active Organization

EpicentRx, Inc.

SciClone Pharmaceuticals (China) Co., Ltd

Inactive Organization

SciClone Pharmaceuticals LLC

Drug Highest PhasePhase 3

First Approval Date-

RegulationFast Track (US)

Structure

Molecular FormulaC5H6BrN3O5

InChIKeyJODKFOVZURLVTG-UHFFFAOYSA-N

CAS Registry925206-65-1

Clinical Trials associated with Nibrozetone

NCT05966194 / RecruitingPhase 2

A Randomized Placebo-Controlled Trial of Two Schedules of RRx-001 for the Attenuation of Severe Oral Mucositis in Patients Receiving Concomitant Chemoradiation for the Treatment of Locally Advanced Squamous Cell Carcinoma of the Oral Cavity or Oropharynx

The purpose of this study is to determine if RRx-001, which is added on to the cisplatin and radiation treatment, reduces the incidence of severe oral mucositis in patients with head and neck cancers. All patients in this study will receive 7 weeks of standard of care radiation therapy given with the chemotherapy agent, cisplatin. Patients will receive RRx-001 or placebo before start of standard of care treatment.

Start Date02 Apr 2024

Sponsor / Collaborator

EpicentRx, Inc.

NCT04525014 / TerminatedPhase 1

A Phase 1 Trial of RRx-001 in Combination With Irinotecan and Temozolomide for Pediatric Patients With Recurrent or Progressive Malignant Solid and Central Nervous System Tumors

The PIRATE study tests the experimental drug RRx-001 in combination with 2 chemotherapy drugs that are commonly used in patients with cancer. RRx-001 has been used alone and with other anti-cancer medicines in adults. However, the investigators do not know what effects it will have in children and young adults.

Start Date26 Jan 2023

Sponsor / Collaborator

EpicentRx, Inc.

[+1]

CTR20221527 / RecruitingPhase 3

REPLATINUM：RRx-001 与含铂类二联疗法序贯给药或含铂类二联疗法单独给药作为小细胞肺癌三线或后续治疗的一项对照、开放、国际随机化 III 期研究

[Translation] REPLATINUM: A controlled, open-label, international, randomized phase III study of RRx-001 administered sequentially with a platinum-based doublet or alone as third-line or subsequent treatment for small cell lung cancer

比较双重主要有效性终点，包括无进展生存期（PFS）和总生存期（OS），PFS 定义为两组从随机分组至疾病进展（RECIST 1.1）或全因死亡之间的时间。疾病进展是由盲态独立中心审查（BICR）根据 RECIST 1.1 评估的，这是PFS 定义的依据。OS 定义为从随机分组至全因死亡的时间。

[Translation]

Dual primary efficacy endpoints were compared, including progression-free survival (PFS) and overall survival (OS), with PFS defined as the time from randomization to disease progression (RECIST 1.1) or death from any cause in both groups. Disease progression was assessed by blinded independent central review (BICR) according to RECIST 1.1, which was the basis for the definition of PFS. OS was defined as the time from randomization to death from any cause.

Start Date25 Aug 2022

Sponsor / Collaborator

SciClone Pharmaceuticals (China) Co., Ltd

100 Clinical Results associated with Nibrozetone

100 Translational Medicine associated with Nibrozetone

100 Patents (Medical) associated with Nibrozetone

Literatures (Medical) associated with Nibrozetone

01 Dec 2024·Biomaterials

CD40 agonist engineered immunosomes modulated tumor microenvironment and showed pro-immunogenic response, reduced toxicity, and tumor free survival in mice bearing glioblastoma

Article

Author: Tyagi, Witty ; Bhattacharyya, Jayanta ; Ganguly, Surajit ; Das, Sanjeev ; Gaur, Vidit

CD40 agonist antibodies (αCD40) have shown promising anti-tumor response in both preclinical and early clinical studies. However, its systemic administration is associated with immune- and hepato-toxicities which hampers its clinical usage. In addition, αCD40 showed low tumor retention and induced PD-L1 expression which makes tumor microenvironment (TME) immunosuppressive. To overcome these issues, in this study, we have developed a multifunctional Immunosome where αCD40 is conjugated on the surface and RRX-001, a small molecule immunomodulator was encapsulated inside it. Immunosomes showed higher tumor accumulation till 96 h of administration and displayed sustained release of αCD40 in vivo. Immunosomes significantly delayed tumor growth and showed tumor free survival in mice bearing GL-261 glioblastoma by increasing the population of CD45⁺CD8⁺ T cells, CD45⁺CD20⁺ B cells, CD45⁺CD11c⁺ DCs and F4/80⁺CD86⁺ cells in TME. Immunosome significantly reduced the population of T-regulatory cells, M2 macrophage, and MDSCs and lowered the PD-L1 expression. Moreover, Immunosomes significantly enhanced the levels of Th1 cytokines (IFN-γ, IL-6, IL-2) over Th2 cytokines (IL-4 and IL-10) which supported anti-tumor response. Most interestingly, Immunosomes averted the in vivo toxicities associated with free αCD40 by lowering the levels of alanine aminotransferase (ALT), aspartate aminotransferase (AST), IL-6, IL-1α and reduced the degree of liver damage. In addition, Immunosomes treated long-term surviving mice showed tumor specific immune memory response which prevented tumor growth upon rechallenge. Our results suggested that this novel formulation can be further explored in clinics to improve in vivo anti-tumor efficacy of αCD40 with long-lasting tumor specific immunity while reducing the associated toxicities.

01 Aug 2024·Journal of Controlled Release

Environmentally responsive hydrogel promotes vascular normalization to enhance STING anti-tumor immunity

Article

Author: Xiao, Zeyu ; Huang, Cuiqing ; Shi, Changzheng ; Hu, Kuan ; Deng, Xiujiao ; Luo, Liangping ; Che, Shuang ; Dong, Qiu ; Wang, Jinghao ; Chen, Jifeng ; Ma, Xiaocong ; Wang, Duo ; Zhang, Ming-Rong ; Zhang, Siqi

The immunosuppressive microenvironment of malignant tumors severely hampers the effectiveness of anti-tumor therapy. Moreover, abnormal tumor vasculature interacts with immune cells, forming a vicious cycle that further interferes with anti-tumor immunity and promotes tumor progression. Our pre-basic found excellent anti-tumor effects of c-di-AMP and RRx-001, respectively, and we further explored whether they could be combined synergistically for anti-tumor immunotherapy. We chose to load these two drugs on PVA-TSPBA hydrogel scaffolds that expressly release drugs within the tumor microenvironment by in situ injection. Studies have shown that c-di-AMP activates the STING pathway, enhances immune cell infiltration, and reverses tumor immunosuppression. Meanwhile, RRx-001 releases nitric oxide, which increases oxidative stress injury in tumor cells and promotes apoptosis. Moreover, the combination of the two presented more powerful pro-vascular normalization and reversed tumor immunosuppression than the drug alone. This study demonstrates a new design option for anti-tumor combination therapy and the potential of tumor environmentally responsive hydrogel scaffolds in combination with anti-tumor immunotherapy.

01 Jul 2024·Advanced Healthcare Materials

An “All‐In‐One” Immunomodulator‐Engineered Clinical Translatable Immunotherapy of Advanced Hepatocellular Carcinoma

Article

Author: Cheng, Yao ; Guo, Pei ; Xie, Ting ; Wei, Hua ; Yu, Cui‐Yun ; Zhang, Haitao ; Lei, Longtianyang ; Huang, Cong ; Wang, Yuqing ; Phann, Thuy Thu ; Tao, Zhenghao ; Gao, Qing

AbstractClinical treatment of advanced hepatocellular carcinoma (HCC) remains a significant challenge. Utilizing 1‐bromoacetyl‐3,3‐dinitroazetidine (RRx‐001) to downregulate the expression of innate immune checkpoint molecule, cluster of differentiation 47 (CD47), provides a powerful means for treating advanced HCC containing abundant immunosuppressive macrophages. Herein engineering of a previously optimized Doxorubicin (DOX)‐delivery nanoplatform based on sodium alginate is reported to further co‐deliver RRx‐001 (biotinylated aldehyde alginate–doxorubicin micelle prodrug nanoplatform, BEA‐D@R) for efficient immunotherapy of advanced HCC. This groundbreaking technique reveals the “all‐in‐one” immunotherapeutic functionalities of RRx‐001. Besides the previously demonstrated functions of downregulating CD47 expression and increasing reactive nitrogen species (RNS) generation, another key function of RRx‐001 for downregulating the expression of the adaptive immune checkpoint molecule programmed cell death 1 ligand 1 (PDL1) is first uncovered here. Combined with the reactive oxygen species (ROS) generation and an upregulated “eat me” signal level of DOX, BEA‐D@R collectively increases RNS generation, enhances T‐cell infiltration, and maximizes macrophage phagocytosis, leading to an average of 40% tumor elimination in a mice model bearing an initial tumor volume of ≈300 mm3 that mimics advanced HCC. Overall, the “all‐in‐one” immunotherapeutic functionalities of a clinical translatable nanoplatform are uncovered for enhanced immunotherapy of advanced HCC.

News (Medical) associated with Nibrozetone

17 Sep 2024

·www.biospace.com

EpicentRx Receives Highly Competitive US Department of Defense (DoD) Translational Award to Develop RRx-001 as a Neuroprotective Medical Countermeasure

The highly competitive award from the CDMRP Toxic Exposures Research Program will fund the development of EpicentRx’s small molecule, RRx-001 (nibrozetone), as a neuroprotective agent and medical countermeasure against neurotoxic chemical exposures. TORREY PINES, Calif. , Sept. 17, 2024 /PRNewswire/ -- EpicentRx and A/Prof. Richard Gordon from the Queensland University of Technology’s Translational Research Institute (QUT-TRI) have been awarded funding from the US Department of Defense Congressionally Directed Medical Research Programs (CDMRP). The Translational Research Award, funded through the CDMRP Toxic Exposures Research Program (TERP), will fund research at both EpicentRx and QUT-TRI in Brisbane, Australia to enable bench-to-bedside development of the proprietary EpicentRx small molecule radio- and chemoprotector, RRx-001 (nibrozetone), as a medical countermeasure for chemical exposures linked to neurodegeneration. Growing evidence suggests that increased exposure to chemicals from industrialization, and in occupations such as military service, firefighting and farming, could be responsible for the rising global incidence of neurological disorders such as Parkinson’s disease and Amyotrophic Lateral Sclerosis. Acute and chronic exposures to specific classes of chemicals such as pesticides, organophosphates, heavy metals and some solvents, have been shown to directly and indirectly damage the central nervous system to either trigger or worsen neurological decline. In both clinical and preclinical studies, RRx-001 has been shown to protect healthy cells from toxicity induced by radiation and chemotherapy. Based on positive results in preclinical models, as well as new insights into the drug’s mode of action, the CDMRP TERP award of $1.6 million for three years will fund further development of RRx-001 and new formulations that can effectively protect the central nervous system and gut-brain axis from damage caused by chemical exposures. “The unique pharmacological properties of RRx-001 and its broad protective activity in the central nervous system make this drug an excellent candidate for neuroprotection and deployment as a medical countermeasure for acute and chronic chemical exposures,” commented co-PI Dr. Richard Gordon , an internationally recognized neuroscientist and toxicologist. “We are honored to be selected for this award from the U.S. DoD,” said Dr. Tony Reid , Chief Executive Officer. “These non-dilutive funds will advance the clinical development of RRx-001 as a potential treatment for veterans that have suffered from the effects of neurotoxicity.” The CDMRP Translational Research Award will enable the next phase development for RRx-001 and builds on ongoing work funded by the Michael J. Fox Foundation, Shake It Up Australia Foundation and FightMND to evaluate the therapeutic efficacy of RRx-001 for neurodegenerative diseases and its protective mechanisms of action in the central nervous system. About EpicentRx: EpicentRx Incorporated is a privately held biopharmaceutical company with two innovation-driven platforms of which nibrozetone (RRx-001) and AdAPT-001 are the lead compounds, respectively. The company’s mission is disease remission, which it hopes to accomplish with novel, well-tolerated therapies that target a diverse range of unmet needs in cancer and non-cancer indications. Nibrozetone (RRx-001), a multimechanistic small molecule, is designed and currently under clinical investigation to preferentially target diseased tissues like tumors even as it shields normal cells from harm. A late-stage clinical trial named KEVLARx is currently ongoing for protection against chemoradiation-induced oral mucositis in first line head and neck cancer. Learn more at . The work was supported by the Assistant Secretary of Defense for Health Affairs endorsed by the Department of Defense, in the amount of $1,599,985.00), through the Toxic Exposures Research Program under Award Nos. HT9425- 24-1-0982 and HT9425-24-1-0983. Opinions, interpretations, conclusions and recommendations are those of the author and are not necessarily endorsed by the Assistant Secretary of Defense for Health Affairs or the Department of Defense. Media Contact: Ashley Thomaz Email: ashleyt@mcspr.com View original content to download multimedia: SOURCE EpicentRx, Inc.

Clinical Study

23 May 2024

·www.prnewswire.com

EpicentRx Announces Oral Presentation for the Most Clinically Advanced TGF-β Ligand Trap, AdAPT-001, at the Upcoming 2024 ASCO Annual Meeting

Data affirm positive immune effects of AdAPT-001 plus a checkpoint inhibitor in sarcomas and triple negative breast cancer with established checkpoint-inhibitor resistance The paucity of immune related adverse events suggests that AdAPT-001 may protect against them. TORREY PINES, Calif., May 23, 2024 /PRNewswire/ -- EpicentRx, a clinical-stage biopharmaceutical company, announced that The American Society of Clinical Oncology (ASCO) has invited Dr. Anthony P. Conley, an MD Anderson Cancer Center (MDACC) Sarcoma Specialist and Lead PI, to give an oral presentation on the unprecedented clinical activity of AdAPT-001 plus an immune checkpoint inhibitor (ICI) in the ongoing Phase 2 open-label BETA PRIME clinical trial that has so far enrolled close to 70 patients. This activity includes complete responses and several durable partial responses in established checkpoint inhibitor-resistant tumor types like sarcoma and triple negative breast cancer, with some patients on treatment for nearly two years. To date, no dose-limiting toxicities or AdAPT-001 related serious adverse events have occurred and only one immune related adverse event (irAE) has been reported. This lack of irAEs suggests that AdAPT-001 may prevent or attenuate ICI-mediated immune attack on normal tissues but not cancerous ones. Lead EpicentRx therapy, AdAPT-001, is the most clinically advanced TGF-β ligand trap that antagonizes the immunosuppressive effects of TGF-β and augments responses to ICIs, even ICIs which patients previously failed. BETA PRIME is a multicenter Phase 2a clinical trial led by Dr. Anthony P. Conley from MDACC and Dr. Lucy B. Kennedy from the Cleveland Clinic. AdAPT-001 is dosed every two weeks in combination with an ICI. "This is incredibly exciting news to have been selected for an oral presentation at ASCO, where the most important trials are presented, discussed, and reviewed," said lead PI, Dr. Anthony P. Conley. "It is a great honor and an indication of the activity, safety, and tolerability of AdAPT-001 in combination with a checkpoint inhibitor. Credit to our clinical trial patients, the EpicentRx team and everyone from MDACC associated with the management of the BETA PRIME clinical trial." The abstract is available on ASCO.org/abstracts. Presentation details: Abstract Number for Publication: 2506 Abstract Title: Phase 1/2 study of the TGF-β-trap-enhanced oncolytic adenovirus, AdAPT-001, plus an immune checkpoint inhibitor for patients with immune refractory cancers. Session Type and Title: Oral Abstract Session – Developmental Therapeutics - Immunotherapy About AdAPT-001 AdAPT-001 is an investigational immunotherapy with a TGF-β receptor-immunoglobulin Fc fusion trap, designed to neutralize isoforms 1 and 3 of the profibrotic, proangiogenic, prohypoxic, and immunosuppressive cytokine, TGF-β, and to sensitize resistant tumors to checkpoint blockade. It is the most clinically advanced TGF-β ligand trap in development. In the ongoing Phase 2 BETA PRIME trial, AdAPT-001 was administered as single-agent and in combination with checkpoint inhibitors to patients with treatment-refractory tumors. Importantly, AdAPT-001 plus checkpoint inhibitors improved toxicity and AE profile over what is typically observed with checkpoint inhibitors. No dose limiting toxicities, AdAPT-001 related serious adverse-events, or dose reductions have been observed to date. About EpicentRx EpicentRx is at the epicenter of innovative drug development with therapies like AdAPT-001 and RRx-001 that target diseases and toxicities of hugely unmet medical need. For more information about the trial and EpicentRx's pipeline, please visit . Business Development Contact: Sa'ar Yaniv EpicentRx [email protected] Media Contact: Ashley Thomaz MCS Healthcare Public Relations [email protected] SOURCE EpicentRx, Inc.

ImmunotherapyPhase 2ASCO

06 Nov 2023

·www.prnewswire.com

EpicentRx To Present Nibrozetone (RRx-001) Data on Parkinson's Disease and ALS/MND at Neuroscience 2023

TORREY PINES, Calif., Nov. 6, 2023 /PRNewswire/ -- EpicentRx, Inc. ("EpicentRx"), a clinical-stage biotechnology company with two therapeutic platforms that address cancer and inflammatory diseases, has been selected for oral and poster presentations at the prestigious Society for Neuroscience's Neuroscience 2023, an international conference taking place in Washington, D.C. from Saturday, November 11 to Wednesday, November 15, 2023. The oral presentation by Dr. Richard Gordon, associate professor at the Queensland University of Technology and an internationally recognized expert on inflammasome signaling in neurodegenerative diseases, will present groundbreaking data on nibrozetone (RRx-001), a Phase 3 small molecule anticancer and chemoprotective agent with central nervous system (CNS) permeability and nanomolar potency against inflammasome activation. "Nibrozetone (RRx-001) has the potential to be an attractive neuroprotective treatment for disease modification of Parkinson's disease, an area of medical research that needs new and improved therapies," said Dr. Richard Gordon. "It has shown great potential against the blood-brain barrier in neurogenerative diseases and I'm looking forward to sharing the latest science and research on this potentially game-changing treatment." Details on the presentation include: Title: The CNS-permeable NLRP3 inhibitor RRx-001 is neuroprotective in experimental models of Parkinson's disease (NANO86.06) Session Title: Parkinson's Disease: Preclinical Models and Therapeutic Strategies Location: WCC 147A Session Date and Time: Wednesday, November 15 at 1:00pm ET EpicentRx will also showcase a poster at the conference titled, "PSTR200.18 – Evaluation of the phase-3 clinical candidate RRx-001 as a novel therapeutic agent for Amyotrophic Lateral Sclerosis." Following Neuroscience 2023, EpicentRx's Chief Executive Officer, Dr. Tony Reid, will present at the 2023 Inflammasome Therapeutics Summit on Thursday, November 30 at 9:30am ET. Dr. Reid's talk is entitled, "Exploring the Development of RRx-001: the NLRP3 Small Molecule Inhibitor for a Variety of Inflammatory Diseases." About Nibrozetone (RRx-001) Nibrozetone (RRx-001) is a highly selective NLRP3 inhibitor, Nrf2 agonist, and hypoxic nitric oxide donor with anti-inflammatory and antioxidant properties. Nibrozetone (RRx-001) is under investigation in a Phase 3 trial for the treatment of small cell lung cancer (SCLC), and a soon-to-start Phase 2b trial for protection against oral mucositis in first line head and neck cancer. It is also under development as a medical countermeasure for toxic exposures, and as a treatment for endometriosis and neurodegenerative diseases like Parkinson's and ALS/MND. About EpicentRx, Inc. EpicentRx Incorporated is a privately held biopharmaceutical company with two innovation-driven platforms of which nibrozetone (RRx-001) and AdAPT-001 are the lead compounds, respectively. The company's mission is disease remission, which it hopes to accomplish with novel, well-tolerated therapies that target a diverse range of unmet needs in cancer and non-cancer indications. Nibrozetone (RRx-001), a multimechanistic small molecule, is designed and currently under clinical investigation to preferentially target diseased tissues like tumors even as it shields normal cells from harm. It is in a Phase 3 trial called REPLATINUM for the treatment of small cell lung cancer (SCLC). A soon-to-start trial is KEVLARx for protection against chemoradiation-induced oral mucositis in first line head and neck cancer. Media Contact: Oliwia Barteczko (908) 234-9900 [email protected] SOURCE EpicentRx, Inc.

Phase 2Phase 3

100 Deals associated with Nibrozetone

External Link

KEGG	Wiki	ATC	Drug Bank
-	-	-	DB12060

R&D Status

10 top R&D records.

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Small Cell Lung Cancer	Phase 3	US	EpicentRx, Inc.	24 Dec 2018
Stomatitis	Phase 2	US	EpicentRx, Inc.	12 Jul 2018
Advanced biliary tract cancer	Phase 2	US	EpicentRx, Inc.	16 Jul 2015
Bile Duct Neoplasms	Phase 2	US	EpicentRx, Inc.	16 Jul 2015
EGFR-mutated non-small Cell Lung Cancer	Discovery	US	EpicentRx, Inc.	01 Jun 2015
Neuroendocrine Tumors	Discovery	US	EpicentRx, Inc.	01 Jun 2015
Refractory Ovarian Carcinoma	Discovery	US	EpicentRx, Inc.	01 Jun 2015
Small Cell Carcinoma	Discovery	US	EpicentRx, Inc.	01 Jun 2015
Metastatic Colorectal Carcinoma	Discovery	US	EpicentRx, Inc.	01 May 2014

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


NCT03515538 (PREVLAR, CTgov)	Phase 2	Squamous cell carcinoma of the oral cavity \| Squamous Cell Carcinoma of the Oropharynx \| Stomatitis	53	Radiation Therapy+Cisplatin for injection+RRx-001 (RRx-001 Pre-Treatment Plus SOC)	rahyfpovht(jrrliyivoz) = vbrxbxfqit zqoporonou (nppmqydshl, xunfwyqhbp - jeirvfundj) View more	-	04 Nov 2024
NCT03515538 (PREVLAR, CTgov)	Phase 2		53	Radiation Therapy+Cisplatin for injection+RRx-001 (RRx-001 Pre-Treatment, 2 Concurrent Doses Plus SOC)	rahyfpovht(jrrliyivoz) = mkvrqxsgui zqoporonou (nppmqydshl, klphbsyvxz - msjkwjzuho) View more	-	04 Nov 2024
NCT01359982 (DINAMIC, CTgov)	Phase 1	Advanced Malignant Solid Neoplasm \| Lymphoma	26	RRx-001	gtydknihqa(kfjuefszgs) = ijqwtwldxg anojtgaumr (wxshhcfhqh, vdtswzjqjc - nozppkmwbl) View more	-	01 Nov 2024
NCT02452970 (EPIC, CTgov)	Phase 2	Advanced biliary tract cancer \| Bile Duct Neoplasms	4	gemcitabine+cisplatin+RRx-001	efypuuavdy(xkghdfzdgq) = blwwuonfyu awcnrpguiu (cheeyujmwn, matfrbyyfj - egxkewtvzt) View more	-	24 Apr 2024
NCT02096354 (ROCKET, Pubmed \| Clin Colorectal Cancer)	Phase 2	Intestinal preparation KRAS mutant type	34	RRx-001 + Irinotecan	(elkscrspih) = tacfvzgqcn umylzqftah (djutvpdecq ) View more	Positive	01 Mar 2023
NCT02096354 (ROCKET, Pubmed \| Clin Colorectal Cancer)	Phase 2	Intestinal preparation KRAS mutant type	34	Regorafenib	(elkscrspih) = rasfrdcjlk umylzqftah (djutvpdecq ) View more	Positive	01 Mar 2023
NCT02489903 (ASCO_GU2023) Manual	Phase 2	Solid tumor Third line	40	RRx-001+etoposide +cisplatin	aopzxncyrt(qehydtceov) = lsiiwhtouh rmywgqgpta (xrrtwfsune ) View more	Positive	21 Feb 2023
NCT02096354 (ROCKET, ASCO_GI2023) Manual	Phase 2	Colorectal Cancer Third line	34	4 mg RRx-001 + irinotecan	(pzozvabfvd) = izayfylnob klntdfzfzy (wiaisgafyc ) View more	Positive	24 Jan 2023
NCT02096354 (ROCKET, ASCO_GI2023) Manual	Phase 2	Colorectal Cancer Third line	34	160 mg regorafenib + irinotecan	(pzozvabfvd) = snjgeamybc klntdfzfzy (wiaisgafyc ) View more	Positive	24 Jan 2023
NCT03515538 (PREVLAR, ASCO2022)	Phase 2	Head and Neck Neoplasms	53	RRx-001 pretreatment only + CRT	(gjdqnebwtr) = RRx-001 were well tolerated with no associated serious adverse events rdrdujtbuz (fovbknzrdq ) View more	Positive	02 Jun 2022
NCT03515538 (PREVLAR, ASCO2022)	Phase 2	Head and Neck Neoplasms	53	Standard-of-care		Positive	02 Jun 2022
NCT02215512 (BRAINSTORM, Pubmed \| Semin Radiat Oncol) Manual	Phase 1/2	Brain metastases	31	Radiation Therapy+RRx-001	(oylxsoyhrc) = rvzyeptgfu znphvbgyhv (clcneeeqcj ) View more	Positive	01 Jul 2020
NCT02801097 (PAYLOAD, ASCO2020) Manual	Phase 1	Advanced Malignant Solid Neoplasm	12	Irinotecan Hydrochloride+RRx 001	(deubfgckft) = 2 events （leukopenia and anemia only related to irinotecan） bskvcndtgk (awmwpsnwvt ) View more	Positive	29 May 2020
NCT02518958 (ASCO2020) Manual	Phase 1	Neoplasms	12	RRx-001+nivolumab	(gknipwvozp) = pain on infusion (33.3%) ifxqtscydq (yzxkwnmbue ) View more	Positive	29 May 2020

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Deal

Boost your decision using our deal data.

view full example data

Core Patent

Boost your research with our Core Patent data.

view full example data

Clinical Trial

Identify the latest clinical trials across global registries.

view full example data

Approval

Accelerate your research with the latest regulatory approval information.

view full example data

Regulation

Understand key drug designations in just a few clicks with Synapse.

view full example data

Chat with Hiro

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis